Compare AGBK & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGBK | CGEM |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2025 | 2020 |
| Metric | AGBK | CGEM |
|---|---|---|
| Price | $6.25 | $19.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $17.20 | ★ $30.13 |
| AVG Volume (30 Days) | 405.3K | ★ 528.4K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $235.22 | $5.20 |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.07 | $5.68 |
| 52 Week High | $12.21 | $19.94 |
| Indicator | AGBK | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 35.48 | 68.97 |
| Support Level | N/A | $11.87 |
| Resistance Level | $7.54 | N/A |
| Average True Range (ATR) | 0.37 | 1.11 |
| MACD | -0.09 | 0.26 |
| Stochastic Oscillator | 13.64 | 83.94 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.